• Explore /
  • Poster
  • / The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.

The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.

Abstract Poster

Authors

null

Michael Michael

Peter MacCallum Cancer Centre, Melbourne, Australia

Michael Michael , Rachel Wong , Sanjeev Singh Gill , Andrew H. Strickland , Nick Pavlakis , Jeremy David Shapiro , Emma Link , Maria Farrell , Samuel Y Ngan , Alexander Graham Heriot , David Goldstein , Catherine Mitchell , Kasmira Wilson , Milton Mui , Robert George Ramsay , Eva Segelov

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Local-Regional Disease

Clinical Trial Registration Number

NCT03299660.

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3616)

DOI

10.1200/JCO.2023.41.16_suppl.3616

Abstract #

3616

Poster Bd #

316

Abstract Disclosures

Similar Posters

First Author: Michael Michael

First Author: Lisa Salvatore

First Author: Paul Bernard Romesser

First Author: Paul Bernard Romesser